In this review, we describe the advances in oral drug delivery approaches for taxanes for successful therapeutic outcome. Taxanes (paclitaxel and docetaxel) have unwanted pharmacokinetic profiles when they are given in their current dosage forms. Taxanes have low bioavailability, are extensively metabolized by CYP3A, and have a high affinity for P-glycoprotein. Regardless of dosage schedule, the overall docetaxel or paclitaxel dose that a patient can tolerate at a given interval remains similar. Currently, there are no commercially available oral taxane nanoformulations, and there are still several challenges to overcome. Nano-based formulations may offer the best solutions to problems involving the safety and effectiveness of taxane delivery. Thus, further research is necessary before such taxane nanoformulations can be manufactured for clinical use.

中文翻译：

---

口服紫杉烷制剂的最新发展：综述。

在这篇综述中，我们描述了紫杉烷类药物口服治疗的成功进展。当紫杉烷类化合物（紫杉醇和多西紫杉醇）以当前剂型给予时，它们具有不需要的药代动力学特征。紫杉烷类药物的生物利用度低，被CYP3A广泛代谢，对P-糖蛋白的亲和力高。无论给药方案如何，患者在给定间隔内可耐受的总多西紫杉醇或紫杉醇的总剂量均保持相似。目前，尚无可商购的口服紫杉烷纳米制剂，仍需克服一些挑战。基于纳米的配方可以为涉及紫杉烷输送的安全性和有效性的问题提供最佳解决方案。从而，